Sarepta Therapeutics Inc — AI technical analysis, September 2026
NYSE/NASDAQ · Biotechnology
AI Recommendation
HOLD
Technical score 15/100
Last price: $20.72 · 52W range $14.68 – $25.32
Short answer
Should you buy SRPT right now? Stockgaide's AI rates SRPT as
HOLD, with a technical score of
15/100 at a last price of $20.72.
The 50-day average is below the 200-day average, and RSI sits at 61.7.
Wall Street's consensus rating is 2.55/5.
Full AI analysis for SRPT
Strategic Conclusion
Recommendation: Hold
Why? The stock is trading above both its 50-day and 200-day moving averages, but the 50-day remains below the 200-day, signaling lingering medium-term downtrend pressure. MACD is slightly bearish and the technical score is a clear sell. Valuation cannot be assessed because P/E is unavailable, and analyst consensus is neutral. This mix argues against buying aggressively and against selling outright.
Ideal profile: Long-term investor who already owns the stock; not attractive for short-term traders given weak momentum signals.
Price range: Current price $20.45 is mid-range relative to the 52-week band ($14.68–$25.32). Support zone is $18.50–$19.25; resistance is near $21.50–$21.80. Stop-loss for existing positions could be placed below $18.40.
Practical action: Hold existing positions. Do not chase at $20.45. Wait for either a confirmed close above $21.50+ or a pullback toward $18.50–$19.25 before considering a new entry.
1. Recent Price & Momentum
Current price $20.45 is about 19% below the 52-week high of $25.32 and 39% above the 52-week low of $14.68.
The stock is in the upper-middle part of its 52-week range, not near the top or bottom.
Short-term scenario: price is above both moving averages, but the SMA50 below SMA200 keeps the medium-term trend bearish. Expect choppy action between $19.25 and $21.50 unless a breakout or breakdown occurs.
2. Valuation (P/E)
P/E TTM is not available for this ticker, so valuation cannot be compared with the sector.
Without earnings visibility, the current price cannot be justified as cheap or expensive on a fundamental basis. The market cap of $2.16B suggests the stock is pricing in future growth expectations rather than current profitability.
3. Technical Analysis
SMA50 ($18.49) is below SMA200 ($19.26) — this is a bearish medium-term structure even though price is above both.
RSI(14) at 56.9 is neutral, leaving room for movement in either direction.
MACD (0.9905) is below its signal line (1.0867), with a negative histogram of -0.0962 — bearish momentum is building.
Technical score: 15/100 → SELL. This is the most decisive negative signal and conflicts with the price being above the moving averages.
4. Analyst Consensus
Mean rating is 2.55/5, with 14 buy, 13 hold, and the remainder likely sell/underperform — effectively neutral.
The analyst view is broadly aligned with the technical picture: no strong conviction to buy, no urgent reason to dump. This supports a Hold rather than a Buy or Sell.
Technical signal details
Rule-based read from price and momentum indicators only — the score behind the AI's recommendation above. Technical score: 15/100 (SELL).
50-day moving average is below the 200-day — medium-term downtrend pressure.
Stockgaide's AI currently rates SRPT as HOLD, with a technical score of 15 out of 100 at a last price of $20.72. This is educational content, not investment advice.
Is SRPT in an uptrend?
SRPT's 50-day moving average (18.52) is below its 200-day moving average (19.27), which points to a medium-term downtrend.
What is SRPT's RSI today?
SRPT has a 14-day RSI of 61.7, which places it in neutral territory (above 70 is overbought, below 30 is oversold).
What do analysts say about SRPT?
Wall Street analysts covering SRPT have a consensus rating of 2.55 out of 5 (1 = Strong Buy), meaning they are neutral — 14 Buy · 13 Hold · 6 Sell.
Where is SRPT trading in its 52-week range?
SRPT last traded at $20.72, against a 52-week range of $14.68 to $25.32 — about 57% of the way up that range.
Get the full AI analysis of SRPT
Price targets, fundamentals deep-dive and an AI-written report — free, no signup.